Micron Biomedical, a company working on painless, microneedle drug delivery, secured a National Institute of Allergy and Infectious Diseases (NIAID) $4.5 million contract through the institute’s Radiation and Nuclear Countermeasures Program, announced July 27. The contract is for the development of a medical countermeasure against radiation injury that combines Micron’s dissolvable microarray delivery technology with Connext‘s TLR5 agonist, xempritolimod, aimed at Acute Radiation Syndrome (ARS), the illness that follows a high-dose radiation…
